iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Compact pharmaceutical factories can make selected medicines in small batches near the point of need, but they are not universal drug printers. Different systems have demonstrated liquid formulations, tablets, or modular manufacturing, and each depends on a defined process, suitable ingredients, quality controls, and regulatory authorization. A 2025 U.S. government report described a Pharmacy on Demand unit deployed at a Mississippi medical center; that is a reported deployment, not proof that any hospital can produce any medicine on demand.
What does “on-demand” drug manufacturing mean?
It describes an operational goal: manufacture a selected medicine in a smaller quantity, closer to where it is needed, rather than relying entirely on large, centralized production and long distribution chains. The equipment may integrate several manufacturing steps in one system, or it may perform only a local step using ingredients made elsewhere.
“Compact pharmaceutical factory” is therefore a broad description, not the name of one standard machine. Some platforms are research prototypes; others are modular systems designed for institutional deployment. The intended benefit is flexibility or a source of reserve capacity for selected products, including medicines affected by shortages. It does not mean that a machine can switch instantly between all drugs, or that production can bypass pharmaceutical quality and regulatory requirements.
Recommended Free Tools
What systems have demonstrated drug production?
Two MIT projects illustrate how different compact systems can be. A separate government-reported deployment provides a more recent example, but the evidence for these cases should not be conflated: their dosage forms, inputs, settings, and reported output differ.
#1 Best Overall
| Example | Dosage form and starting material | Reported scale or dimensions | What the evidence establishes |
|---|---|---|---|
| MIT flow-based system, reported in 2016 | Solutions or suspensions; integrated chemical synthesis through final formulation | MIT reported about 1,000 doses of a given drug in 24 hours. | MIT reported making Benadryl, lidocaine, Valium, and Prozac. The system included synthesis, purification, filtration, drying, and formulation, with ultrasound monitoring used to check concentration. This is a dated report about that system, not a current commercial specification. |
| Compact tablet system, peer-reviewed study indexed by PubMed in 2018 | Tablets made from drug crystals | 72.4 × 53.3 × 134.6 cm; the study reported a scale of hundreds to thousands of tablets per day. | The study demonstrated ibuprofen and diazepam tablets and reported that each met U.S. Pharmacopeia standards. It was a different system from MIT’s 2016 liquid-manufacturing platform. |
| On Demand Pharmaceuticals Pharmacy on Demand, reported by HHS/ASPR in August 2025 | Modular platform; the report does not specify a single dosage form or a universal input configuration. | HHS/ASPR said the platform could be as large as a tractor trailer; a production rate was not stated in that report. | HHS/ASPR reported deployment at Northern Mississippi Medical Center to produce medicines in shortage in real time. The report does not establish broad commercial availability or independent performance at other sites. |
| NIST point-of-care manufacturing framework | Personalized doses produced locally using certified API material manufactured centrally under rigorous GMP controls | A production rate and unit dimensions were not stated in the NIST framework. | The framework describes a model for local dose production at hospitals, pharmacies, or similar sites; it is not a report of a particular universal drug-making machine. |
How can a small factory make medicine?
A platform connects a defined set of manufacturing operations into a controlled process. The MIT system reported in 2016 integrated chemical synthesis through liquid formulation. The 2018 tablet study took a different route: it started with drug crystals and manufactured tablets. In the NIST point-of-care framework, the active pharmaceutical ingredient (API) is made centrally, then supplied to a local site for dose production. These are distinct manufacturing models, not interchangeable descriptions of one machine.
Which steps occur on site matters. A system that synthesizes an API locally has different inputs and process controls from one that receives centrally manufactured API and makes a finished dose. Product changes can also require different recipes, modules, or validated processes; “on demand” does not establish that a new medicine can be made simply by loading a different file.
Could a hospital make medicine during a shortage?
Potentially, for selected products and within an authorized operating model. HHS’s Administration for Strategic Preparedness and Response (ASPR) reported in August 2025 that On Demand Pharmaceuticals’ Pharmacy on Demand platform had been deployed at Northern Mississippi Medical Center to produce medicines in shortage in real time. ASPR also described federal support for domestic API and finished-dose capacity.
That report is meaningful evidence of a deployment, but it does not show that every hospital has the equipment, staff, ingredients, approvals, or validated processes needed to manufacture a shortage medicine. Nor does it establish the unit’s output for each product, performance at other facilities, or general availability for purchase.
What keeps locally made medicine safe and consistent?
Moving manufacturing closer to care does not remove the need to control the process or verify the finished medicine. The controls depend on the platform and production model, but the central questions include whether inputs meet specifications, whether the process consistently produces the intended dose and quality, and whether the results are documented and checked.
- Suitable inputs: Ingredients must be appropriate for the defined process. In the NIST framework, API material is produced centrally under rigorous good manufacturing practice (GMP) controls before being supplied to local sites.
- Process monitoring: Operators need controls appropriate to the production steps. NIST discusses checking incoming material and monitoring the quantities dispensed.
- Finished-product verification: Analytical checks are needed to verify quality and quantity. The MIT 2016 report, for example, described ultrasound monitoring to check concentration; that detail is specific to that reported system.
- Validation and records: The process and its documentation must support consistent manufacture under the applicable quality system. Changing products or operating conditions cannot be assumed to preserve a validated process.
The FDA describes advanced manufacturing approaches—including continuous manufacturing, modularization, and point-of-care opportunities—as ways that may improve quality, efficiency, shortage response, or time to market. It also identifies networks of smaller manufacturing sites as a possible way to build reserve capacity. These are potential benefits, not guarantees that a particular compact platform will achieve them.
Rank #4
What is the regulatory status?
Rules depend on jurisdiction, product, manufacturing arrangement, and site. In the United States, FDA’s 2022 discussion paper on distributed and point-of-care manufacturing was issued to solicit stakeholder input. FDA states that it is not draft or final guidance and is not intended to convey current requirements or policy. It should not be treated as an authorization pathway or a statement that local production is exempt from existing requirements.
FDA’s FRAME initiative lists end-to-end continuous manufacturing, distributed manufacturing, distributed units at nontraditional host sites such as healthcare facilities, and AI among its focus areas. The initiative page lists a proposed rule issued in July 2026 concerning registration and listing requirements for establishments engaged in distributed manufacturing. It is a proposal, not a final rule.
Best Value
The United Kingdom’s 2025 overview discusses a separate licensing framework for modular manufacture and point-of-care medicinal products, including approved units and sites, manufacturing controls, GMP, and master files. Those provisions are a jurisdiction-specific example and should not be read as U.S. law.
What compact drug factories can—and cannot—solve
These platforms could complement conventional manufacturing by adding flexible or geographically closer capacity for selected medicines. The clearest examples span two MIT demonstrations with different product forms and a 2025 government-reported deployment, rather than one device capable of making every drug.
The evidence does not establish current prices, comparative economics, general commercial availability of the MIT prototypes, or a production rate that applies across platforms. Output figures should be understood only in the context of the specific dated system that reported them. Whether a compact factory can help with a particular shortage depends on the medicine, process, inputs, site, quality system, and regulatory authorization.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteQuick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
